Asymchem(002821)2025-01-27 11:45Financial Performance - The company expects net profit attributable to shareholders to be between CNY 850 million and CNY 1.05 billion, a decrease of 54%-63% compared to the previous year[3]. - The projected operating revenue for 2024 is between CNY 5.8 billion and CNY 6 billion, representing a decline of 23%-25% year-on-year[5]. - The basic earnings per share are estimated to be between CNY 2.50 and CNY 3.00, down from CNY 6.26 in the same period last year[3]. Revenue Growth and Orders - The company achieved a year-on-year revenue growth of approximately 20% in Q4 2024, despite an overall decline in annual revenue[5]. - New orders signed throughout the year increased by approximately 20%, with growth in orders from European and American markets exceeding the overall order growth rate[6]. - The small molecule CDMO business showed a year-on-year growth of about 11% after excluding the impact of large orders from the previous year[5]. Emerging Business and Capacity Utilization - The emerging business revenue declined, and some segments are still ramping up, leading to lower capacity utilization and reduced gross margins[6]. - The company continues to invest heavily in new technology research and development, resulting in increased R&D expenses[6]. Business Trends and Developments - The chemical macromolecule business is showing positive trends in areas such as peptides, nucleic acids, and ADCs, with Q4 revenue accounting for over 45% of total annual revenue[6]. - The company’s UK Sandwich site began operations in the second half of the year and is currently in the ramp-up phase[6].